COMPANY
Eli Lilly & Company
Eli Lilly & Company: bulk ingredient labeler, US labeler, trial sponsor, warning letter recipient, recalling firm for Tirzepatide, Dulaglutide, Teriparatide, Calcitonin, Ciclosporin, Exenatide, Glucagon, Goserelin, Insulin degludec, Liraglutide, Octreotide, Retatrutide, Semaglutide, as stated by public registers.
Also written as: Eli Lilly and Company.
BULK INGREDIENT LABELER
Lists the bulk active ingredient with FDA (NDC directory).
| Tirzepatide | tirzepatide, BULK INGREDIENT Regulator openFDA |
|---|
US LABELER
Lists a finished product with FDA (NDC directory); can be a maker, repackager or distributor.
| Dulaglutide | Dulaglutide, DRUG FOR FURTHER PROCESSING Regulator openFDA |
|---|---|
| Dulaglutide | Trulicity, BLA Regulator openFDA |
| Teriparatide | Forteo, NDA Regulator openFDA |
| Tirzepatide | Mounjaro KwikPen, NDA Regulator openFDA |
| Tirzepatide | Mounjaro, NDA Regulator openFDA |
| Tirzepatide | Zepbound KwikPen, NDA Regulator openFDA |
| Tirzepatide | Zepbound, NDA Regulator openFDA |
| Tirzepatide | ZEPBOUND, NDA Regulator openFDA |
TRIAL SPONSOR
Sponsors registered clinical trials of the peptide.
| Calcitonin | 4 registered trials Trial register ClinicalTrials.gov |
|---|---|
| Ciclosporin | 1 registered trial Trial register ClinicalTrials.gov |
| Dulaglutide | 39 registered trials Trial register ClinicalTrials.gov |
| Exenatide | 4 registered trials Trial register ClinicalTrials.gov |
| Glucagon | 17 registered trials Trial register ClinicalTrials.gov |
| Goserelin | 1 registered trial Trial register ClinicalTrials.gov |
| Insulin degludec | 17 registered trials Trial register ClinicalTrials.gov |
| Liraglutide | 7 registered trials Trial register ClinicalTrials.gov |
| Octreotide | 1 registered trial Trial register ClinicalTrials.gov |
| Retatrutide | 19 registered trials Trial register ClinicalTrials.gov |
| Semaglutide | 9 registered trials Trial register ClinicalTrials.gov |
| Teriparatide | 36 registered trials Trial register ClinicalTrials.gov |
| Tirzepatide | 79 registered trials Trial register ClinicalTrials.gov |
WARNING LETTER RECIPIENT
Received an FDA warning letter naming the peptide.
| Liraglutide | False & Misleading Claims/Misbranded, 2025-09-09 Regulator FDA warning letters |
|---|---|
| Semaglutide | False & Misleading Claims/Misbranded, 2025-09-09 Regulator FDA warning letters |
| Tirzepatide | False & Misleading Claims/Misbranded, 2025-09-09 Regulator FDA warning letters |
RECALLING FIRM
Recalled a product naming the peptide (FDA enforcement report).
| Dulaglutide | Class II recall, Terminated, 2021-09-01 Regulator openFDA |
|---|---|
| Glucagon | Class I recall, Terminated, 2021-10-20 Regulator openFDA |
What a register states, not an endorsement or an accusation by this site. All companies.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.